Furthermore, the new FIGO classification of 2023 has, for the first time in gynecological tumors, included a staging system based not only on disease extent but also on histopathological (such as histotype, grade, LVSI status) and molecular features, namely, POLE mutations, and p53 status [21]. Here, TP53 is linked to female reproductive system neoplasm.